China Medicine Corp. (CHME) Stock

About China Medicine Corp.

China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.

China Medicine Corp. is headquartered in CN.

China Medicine Corp. (CHME) stock trades at $0.02 with a market capitalization of $474241. The stock is valued at a price-to-earnings (P/E) ratio of 0.18, price-to-book of 0.01, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.00 and $0.04, and currently trades 50.0% below its 52-week high.

On profitability, China Medicine Corp. generates a return on equity (ROE) of 3.91%, return on capital employed of 23.40%, an operating margin of 18.94%, a net profit margin of 2.65%.

Official website: www.cmc621.com